Hans Berger Dept. of Neurology, University Hospital Jena

The Neuromuscular Unit provides primary and secondary care for patients with motor neurone diseases and neuromuscular diseases. We cover the full range of diagnostics, provide ICU treatment, feeding tube placement and NIV services, regular clinical visits, and coordination of support measures. Clinical trials, clinical research and basic research in animal and cell models form a bench to bedside concept which is integrated into national, european and international consortia (ie. MND-NET, SOPHIA, NISALS, ERMCC-NDEG, PYRAMID, ONWebDUALS).

Hans Berger Dept. of Neurology, University Hospital Jena
Foundation year

2007

Director

Prof. Dr. med. Otto W. Witte

Principal investigator

PD Dr. med. Julian Grosskreutz

Contact information
Address

Erlanger Allee 101
07747, Jena
Germany

Contact

Dr. rer. nat. Beatrice Stubendorff

Phone

+49 3641 9323488

Fax

+49 3641 9323477

Email als-neuro@med.uni-jena.de
Website Visit the website

Publications

  • Native chromatographic sample preparation of serum, plasma and cerebrospinal fluid does not comprise a risk for proteolytic biomarker loss. Pesek J, Krüger T, Krieg N, Schiel M, Norgauer J, Großkreutz J, Rhode H. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Feb 18;923-924C:102-109. doi: 10.1016/j.jchromb.2013.02.014. [Epub ahead of print]
  • MRI in amyotrophic lateral sclerosis: more than a promise. Grosskreutz J. J Neurol Neurosurg Psychiatry. 2012 Dec 25. [Epub ahead of print]
  • Diffusion tensor imaging patterns differ in bulbar and limb onset amyotrophic lateral sclerosis. Prell T, Peschel T, Hartung V, Kaufmann J, Klauschies R, Bodammer N, Kollewe K, Dengler R, Grosskreutz J. Clin Neurol Neurosurg. 2012 Dec 21. doi:pii: S0303-8467(12)00609-9. 10.1016/j.clineuro.2012.11.031.
  • Longitudinal diffusion tensor imaging in amyotrophic lateral sclerosis. Keil C, Prell T, Peschel T, Hartung V, Dengler R, Grosskreutz J. BMC Neurosci. 2012 Nov 8;13:141. doi: 10.1186/1471-2202-13-141.
  • Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery. Krüger T, Lautenschläger J, Grosskreutz J, Rhode H. Proteomics Clin Appl. 2013 Jan;7(1-2):123-35. doi: 10.1002/prca.201200067.

Restricted information

Serving population
Serving population

1.000.0000 or more

Patient resources
Population based register

No

Clinic based register

Yes

Geographically matched controls

Yes

Number of muscle samples

50

Number of skin samples

20

Number of spinal cord samples

10

Number of brain samples

10

Banks

Type ALS Patients Controls Other
DNA Bank 300 150 200
CSF Bank 80 30 100
Serum Bank 200 100 100
RNA Bank 30 100 100
Research activities
Clinical management research

Yes

Neuro epidemiology

Yes

Neuro physiology

Yes

Neuro imaging

Yes

Neuro psychology

Yes

Neuro pathology

Yes

Genomics

Yes

Transcriptomics

Yes

Metabolomics

Yes

Clinical Trials - Industry sponsored

Name Type Patients
EMPOWER EMPOWER 23
ENVISION ENVISION 16
NoGo-A NoGo-A 14

Clinical Trials - Investigator initiated

Name Type Patients
ALS GERP ALS GERP 22
Rasagilin Rasagilin 15
JERN (Jena Nutrition Assessment Trial) JERN (Jena Nutrition Assessment Trial) 50
LIPCAL-ALS LIPCAL-ALS 20